Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 9 for:    MECLIZINE
Previous Study | Return to List | Next Study

Meclizine for Hepatocellular Carcinoma (OPTIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03253289
Recruitment Status : Recruiting
First Posted : August 17, 2017
Last Update Posted : June 7, 2019
Sponsor:
Information provided by (Responsible Party):
Brandon G. Smaglo, Baylor College of Medicine

Brief Summary:

Meclizine hydrochloride is an antihistamine widely used for treatment of vertigo and motion sickness. In HCC it has been used for anti-emetic effects, but it is used here as a CAR (constitutive androstane receptor) inverse agonist.

The hypothesis of this study is that meclizine, a CAR inverse agonist, will have a beneficial therapeutic effect in patients with hepatocellular carcinoma who are candidates for surgical resection, ablation or TACE (trans-arterial chemoembolization) by blocking tumorigenesis and inducing apoptosis.


Condition or disease Intervention/treatment Phase
Carcinoma, Hepatocellular Drug: Meclizine Oral Tablet Phase 1

Detailed Description:

The constitutive androstane receptor (CAR, NR1I3) is a nuclear receptor that plays a central role in hepatic detoxification of potentially toxic compounds, or xenobiotics. Chronic CAR activation by specific agonists induces tumors in wild type mice, and strongly promotes hepatocarcinogenesis in combination with initiating mutagens. Both effects are absent in CAR null mice. These tumorigenic effects are associated with an acute induction of hepatocyte proliferation in mice. Preliminary results using partially humanized mice demonstrate a very similar proliferative effect of CAR activation in human hepatocytes.

The transcriptional activity of CAR can be reversed by specific inverse agonists. These ligands are analogous to steroid receptor antagonists, converting the transcriptional activation of the agonist bound receptor into transcriptional repression. These compounds are termed inverse agonists because they do not depend on the presence of agonist ligands to exert their repressive effects. Mouse and human CAR proteins are more divergent than other nuclear receptors, and respond to quite different profiles of agonists and inverse agonists. Preliminary results demonstrate that the specific mouse CAR inverse agonist androstanol blocks proliferation and induces apoptosis in mouse liver tumors. This raises the possibility that targeting CAR may represent a new modality of treatment for hepatocellular cancer (HCC) analogous to estrogen and androgen receptor antagonists in breast and prostate cancers. Meclizine, a widely used antihistamine medication for vertigo and motion sickness, is an inverse agonist ligand of human CAR. Investigators hypothesize that reversing CAR function with meclizine will have a beneficial therapeutic effect in patients with HCC by blocking proliferation and inducing apoptosis.

Investigators therefore propose a novel window of opportunity trial in which biopsy proven HCC patients will receive oral meclizine daily for 28 days while awaiting surgical resection, radiofrequency ablation, or transarterial chemoembolization. The primary test of treatment outcome will be the predicted decrease in expression of downstream CAR target genes (CYP2B6, MYC and FOXM1) in pre and post treatment tumor specimens. Investigators will also measure the change in tumor proliferation and apoptosis by measuring Ki-67 proliferation index and TUNEL assays (terminal deoxynucleotidyl transferase dUTP Nick-End Labeling assay), serum levels of AFP and GDF 15, and overall tumor response by imaging. HCC is the most rapidly increasing cause of cancer mortality in the United States and medical treatment options are limited. Successful completion of this study may identify a new approach to treatment of HCC.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Window of Opportunity Trial With Meclizine in Hepatocellular Carcinoma
Actual Study Start Date : October 13, 2017
Estimated Primary Completion Date : December 1, 2021
Estimated Study Completion Date : December 1, 2026


Arm Intervention/treatment
Experimental: Meclizine 100 mg Drug: Meclizine Oral Tablet
All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 21 days.




Primary Outcome Measures :
  1. Change in mRNA levels [ Time Frame: day1 and last day of treatment(last day would be one time point between day 21 and day 28 of treatment) ]
    Quantitative real time PCR(qPCR) can give change in expression level compared to control Delta CT value. Downstream target genes of CAR (CYP2b6,c-Myc, and FoxM) will be measured by qPCR in the pre and post treatment Hepatocellular cancer tissue specimens. The qPCR machine measures the intensity of fluorescence emitted by the probe at each cycle. The Ct measure is a determined PCR cycle and represents the basic result of a qPCR experience. The Ct is the value where the PCR curve crosses the threshold.


Secondary Outcome Measures :
  1. Change in Ki-67 proliferation index [ Time Frame: day1 and last day of treatment(last day would be one time point between day 21 and day 28 of treatment) ]
    The proliferative index is a measure of the number of cells in a tumor that are dividing (proliferating).

  2. change in TUNEL assay [ Time Frame: day1 and last day of treatment(last day would be one time point between day 21 and day 28 of treatment) ]
  3. Tumor response [ Time Frame: day1 and last day of treatment(last day would be one time point between day 21 and day 28 of treatment) ]
    Assess tumor response by RECIST criteria

  4. Change in Serum AFP [ Time Frame: baseline, day1, day15 of treatment ]
    This will be measured in peripheral blood samples

  5. Change in growth differentiation factor (GDF-15) [ Time Frame: baseline and day22(between day 22-24) of treatment ]
    This will be measured in peripheral blood samples

  6. A panel of CAR downstream target genes [ Time Frame: day1 and last day of treatment(last day would be one time point between day 21 and day 28 of treatment) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient must have imaging (MRI or CT abdomen liver protocol) confirmed Hepatocellular carcinoma. Patients cannot have metastatic HCC.
  2. Patients must have measurable disease, defined as tumor mass which is >10 mm with spiral CT scan or MRI. Baseline imaging scan must be within 6 weeks of registration.
  3. Patients must be greater than 18 years of age.
  4. ECOG Performance status less than/equal to 2 (Karnofsky greater than 60%).
  5. Patients must have normal organ and marrow function as defined below, within 21 days of registration: Leukocytes greater than 3,000/mcL; ANC greater than 1,500/mcL; Platelets greater than 50,000/mcL; Hemoglobin greater than/equal to 8 g/dL; ALT(SGPT) less than/equal to 5X IULN and AST (SGOT) less than/equal to 5X IULN; Creatinine less than/equal to 2X IULN or Creatinine clearance greater than 60 mL/min for patients with creatinine levels greater than IULN; Child Pugh Class A (5-6 points) or B (7 points); INR less than/equal to 2.3; Albumin greater than 2.8 g/dL; Total bilirubin less than/equal to 3X IULN.
  6. Patients must be candidate for surgical resection, ablation, and TACE.
  7. Patients should have life expectancy greater than/equal to 10 weeks.
  8. Willingness to Use Contraception: The effects of Meclizine on the developing human fetus at the recommended therapeutic dose are unknown. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment with meclizine. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. If a male participant impregnates his partner he should inform his treating physician immediately.
  9. Subjects must be informed of the investigational nature of this study, and must sign and give written informed consent in accordance with institutional and federal guidelines.
  10. Patients taking medications with a narrow therapeutic index including warfarin, digoxin, phenobarbital, carbamazepine, and cyclosporine are not excluded but should be monitored carefully.
  11. Antiviral therapy for HCV and HBV is allowed, but patient should not be on interferon

Exclusion Criteria:

  1. Patients must have no prior history of treatment for HCC (treatment naive).
  2. Patients may not be receiving any other anti-cancer therapy.
  3. Patients may not be receiving any other investigational agents.
  4. Patients must not be taking Rifampin or St John's Wort.
  5. Patient must not have a history of allergic reactions like anaphylaxis attributed to compounds of similar chemical or biologic composition to Meclizine such as antihistamine drugs.
  6. Patient must not be a candidate for liver transplant.
  7. Child Pugh Class B (8,9) and Class C are excluded
  8. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with meclizine.
  9. Patient must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction or cerebrovascular accident within 6 months prior to registration, cardiac arrhythmia, glaucoma, asthma or psychiatric illness/social situations that would limit compliance with study requirements.
  10. Pregnant women are excluded from this study because meclizine is a Class B agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with meclizine, breastfeeding should be discontinued if the mother is treated with meclizine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03253289


Contacts
Layout table for location contacts
Contact: Brandon Smaglo, MD 713-798-3750 smaglo@bcm.edu

Locations
Layout table for location information
United States, Texas
Baylor Clinic Recruiting
Houston, Texas, United States, 77030
Contact: Brandon Smaglo, MD    713-798-3750    smaglo@bcm.edu   
Baylor St. Luke's Medical Center Recruiting
Houston, Texas, United States, 77030
Contact: Brando Smaglo, MD    713-798-3750    smaglo@bcm.edu   
Dan L. Duncan Cancer Center at Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Clinical Trials Office - Dan L. Duncan Cancer Center at Baylor    713-798-1297      
Sponsors and Collaborators
Brandon G. Smaglo
Investigators
Layout table for investigator information
Principal Investigator: Brandon Smaglo, MD Baylor College of Medicine

Layout table for additonal information
Responsible Party: Brandon G. Smaglo, Assistant Professor of Medicine - Hematology and Oncology, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT03253289     History of Changes
Other Study ID Numbers: H-40370
First Posted: August 17, 2017    Key Record Dates
Last Update Posted: June 7, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD will not be shared, as indicated above.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Brandon G. Smaglo, Baylor College of Medicine:
Hepatocellular carcinoma, HCC, Liver cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Meclizine
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Allergic Agents